Market Research

Canine Atopic Dermatitis Market Size, Share & Trends Analysis Report By Product (Glucocorticoids, Antihistamines), By Type, By Dog Breed, By Mode Of Administration, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Best Price Guarantee Length Publisher Published Date SKU
from $5,950 100 Pages Grand View Research May, 2025 GV20110276
Best Price Guarantee
Price from $5,950
Length 100 Pages
Publisher Grand View Research
Published Date May, 2025
SKU GV20110276

Canine Atopic Dermatitis Market Growth & Trends

The global canine atopic dermatitis market size is anticipated to reach USD 8.78 billion by 2030 and expand at a CAGR of 10.6% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of canine atopic dermatitis and advancements in veterinary medicine are driving market growth. Increasing cases of skin allergies in dogs have led to higher demand for effective treatments. Innovations such as monoclonal antibodies and improved immunosuppressants enhance therapeutic outcomes, fueling market expansion. Research and development efforts continue to drive novel therapies, improving treatment efficacy and accessibility.

Growing pet ownership and increased awareness among pet owners propel the canine atopic dermatitis market. As more households adopt dogs, the demand for dermatological care rises. Pet owners are becoming more proactive in seeking treatment, leading to higher adoption of specialized therapies. The rise in pet healthcare spending and improved diagnostic capabilities further contribute to market growth.

The increasing focus on companion animal wellness and expanding veterinary healthcare infrastructure are expected to drive market growth. Enhanced veterinary facilities and specialized dermatology clinics improve access to advanced treatments. Rising investments in pet healthcare further support the market expansion, with pharmaceutical companies developing innovative solutions to meet growing demand.

Canine Atopic Dermatitis Market Report Highlights

  • By product, the glucocorticoids segment led the market with the largest revenue share of 38.3% in 2024, fueled by its widespread use in managing inflammation and allergic reactions in dogs.
  • The MAbs segment is set to be the fastest-growing segment during the forecast period,attributed to its targeted approach to managing allergic reactions.
  • By type, the prescription segment dominated the market with the largest share in 2024, driven by the growing reliance on veterinarian-recommended treatments.
  • The OTC segment is set to witness the fastest growth from 2025 to 2030 due to increasing preference for accessible and affordable treatments.
  • North America accounted for the largest revenue share of 40.4% in 2024, propelled by its advanced veterinary healthcare infrastructure and high pet ownership rates.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Type
1.2.3. Dog Breed
1.2.4. Mode of Administration
1.2.5. Indication
1.2.6. Distribution Channel
1.2.7. Regional Scope
1.2.8. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product Outlook
2.2.2. Type Outlook
2.2.3. Dog Breed Outlook
2.2.4. Mode of Administration Outlook
2.2.5. Indication Outlook
2.2.6. Distribution Channel Outlook
2.2.7. Regional Outlook
2.3. Competitive Scenario
Chapter 3. Canine Atopic Dermatitis Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Canine Atopic Dermatitis Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
Chapter 4. Canine Atopic Dermatitis Market: Product Estimates & Trend Analysis
4.1. Product Segment Dashboard
4.2. Canine Atopic Dermatitis Market: Product Movement Analysis
4.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
4.4. Glucocorticoids
4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. Antihistamines
4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.6. Immunosuppressants
4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.7. MAbs
4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. Canine Atopic Dermatitis Market: Type Estimates & Trend Analysis
5.1. Type Segment Dashboard
5.2. Canine Atopic Dermatitis Market: Type Movement Analysis
5.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Million)
5.4. Prescription
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. OTC
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. Canine Atopic Dermatitis Market: Dog Breed Estimates & Trend Analysis
6.1. Dog Breed Segment Dashboard
6.2. Canine Atopic Dermatitis Market: Dog Breed Movement Analysis
6.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Dog Breed, 2018 to 2030 (USD Million)
6.4. German Shepherd
6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Terriers
6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6. Retrievers
6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7. Others
6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. Canine Atopic Dermatitis Market: Mode of Administration Estimates & Trend Analysis
7.1. Mode of Administration Segment Dashboard
7.2. Canine Atopic Dermatitis Market: Mode of Administration Movement Analysis
7.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Mode of Administration, 2018 to 2030 (USD Million)
7.4. Oral
7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5. Topical
7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6. Injectable
7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 8. Canine Atopic Dermatitis Market: Indication Estimates & Trend Analysis
8.1. Indication Segment Dashboard
8.2. Canine Atopic Dermatitis Market: Indication Movement Analysis
8.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Indication, 2018 to 2030 (USD Million)
8.4. Ectoparasites
8.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
8.5. Food Allergy
8.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
8.6. Allergic Skin Infections
8.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
8.7. Others
8.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 9. Canine Atopic Dermatitis Market: Distribution Channel Estimates & Trend Analysis
9.1. Distribution Channel Segment Dashboard
9.2. Canine Atopic Dermatitis Market: Distribution Channel Movement Analysis
9.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Distribution Channel, 2018 to 2030 (USD Million)
9.4. Veterinary Hospitals/Clinics
9.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.5. Retail
9.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
9.6. E-commerce
9.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 10. Canine Atopic Dermatitis Market: Regional Estimates & Trend Analysis
10.1. Regional Market Dashboard
10.2. Regional Market Share Analysis, 2024 & 2030
10.3. Canine Atopic Dermatitis Market by Region: Key Takeaways
10.4. North America
10.4.1. U.S.
10.4.1.1. Key Country Dynamics
10.4.1.2. Regulatory Framework/ Reimbursement Structure
10.4.1.3. Competitive Scenario
10.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.4.2. Canada
10.4.2.1. Key Country Dynamics
10.4.2.2. Regulatory Framework/ Reimbursement Structure
10.4.2.3. Competitive Scenario
10.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.4.3. Mexico
10.4.3.1. Key Country Dynamics
10.4.3.2. Regulatory Framework/ Reimbursement Structure
10.4.3.3. Competitive Scenario
10.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.5. Europe
10.5.1. U.K.
10.5.1.1. Key Country Dynamics
10.5.1.2. Regulatory Framework/ Reimbursement Structure
10.5.1.3. Competitive Scenario
10.5.1.4. U.K. Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.5.2. Germany
10.5.2.1. Key Country Dynamics
10.5.2.2. Regulatory Framework/ Reimbursement Structure
10.5.2.3. Competitive Scenario
10.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.5.3. France
10.5.3.1. Key Country Dynamics
10.5.3.2. Regulatory Framework/ Reimbursement Structure
10.5.3.3. Competitive Scenario
10.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.5.4. Italy
10.5.4.1. Key Country Dynamics
10.5.4.2. Regulatory Framework/ Reimbursement Structure
10.5.4.3. Competitive Scenario
10.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.5.5. Spain
10.5.5.1. Key Country Dynamics
10.5.5.2. Regulatory Framework/ Reimbursement Structure
10.5.5.3. Competitive Scenario
10.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.5.6. Denmark
10.5.6.1. Key Country Dynamics
10.5.6.2. Regulatory Framework/ Reimbursement Structure
10.5.6.3. Competitive Scenario
10.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.5.7. Sweden
10.5.7.1. Key Country Dynamics
10.5.7.2. Regulatory Framework/ Reimbursement Structure
10.5.7.3. Competitive Scenario
10.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.5.8. Norway
10.5.8.1. Key Country Dynamics
10.5.8.2. Regulatory Framework/ Reimbursement Structure
10.5.8.3. Competitive Scenario
10.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.6. Asia Pacific
10.6.1. Japan
10.6.1.1. Key Country Dynamics
10.6.1.2. Regulatory Framework/ Reimbursement Structure
10.6.1.3. Competitive Scenario
10.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.6.2. China
10.6.2.1. Key Country Dynamics
10.6.2.2. Regulatory Framework/ Reimbursement Structure
10.6.2.3. Competitive Scenario
10.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.6.3. India
10.6.3.1. Key Country Dynamics
10.6.3.2. Regulatory Framework/ Reimbursement Structure
10.6.3.3. Competitive Scenario
10.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.6.4. Australia
10.6.4.1. Key Country Dynamics
10.6.4.2. Regulatory Framework/ Reimbursement Structure
10.6.4.3. Competitive Scenario
10.6.4.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.6.5. South Korea
10.6.5.1. Key Country Dynamics
10.6.5.2. Regulatory Framework/ Reimbursement Structure
10.6.5.3. Competitive Scenario
10.6.5.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.6.6. Thailand
10.6.6.1. Key Country Dynamics
10.6.6.2. Regulatory Framework/ Reimbursement Structure
10.6.6.3. Competitive Scenario
10.6.6.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.7. Latin America
10.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.7.2. Brazil
10.7.2.1. Key Country Dynamics
10.7.2.2. Regulatory Framework/ Reimbursement Structure
10.7.2.3. Competitive Scenario
10.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.7.3. Argentina
10.7.3.1. Key Country Dynamics
10.7.3.2. Regulatory Framework/ Reimbursement Structure
10.7.3.3. Competitive Scenario
10.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.8. Middle East and Africa
10.8.1. Middle East and Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.8.2. South Africa
10.8.2.1. Key Country Dynamics
10.8.2.2. Regulatory Framework/ Reimbursement Structure
10.8.2.3. Competitive Scenario
10.8.2.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.8.3. Saudi Arabia
10.8.3.1. Key Country Dynamics
10.8.3.2. Regulatory Framework/ Reimbursement Structure
10.8.3.3. Competitive Scenario
10.8.3.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.8.4. UAE
10.8.4.1. Key Country Dynamics
10.8.4.2. Regulatory Framework/ Reimbursement Structure
10.8.4.3. Competitive Scenario
10.8.4.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
10.8.5. Kuwait
10.8.5.1. Key Country Dynamics
10.8.5.2. Regulatory Framework/ Reimbursement Structure
10.8.5.3. Competitive Scenario
10.8.5.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 11. Competitive Landscape
11.1. Recent Developments & Impact Analysis, By Key Market Participants
11.2. Company/ Competition Categorization
11.3. Vendor Landscape
11.3.1. Key Company Heat Map Analysis, 2024
11.4. Company Profiles
11.4.1. Zoetis Services LLC
11.4.1.1. Company Overview
11.4.1.2. Financial Performance
11.4.1.3. Product Benchmarking
11.4.1.4. Strategic Initiatives
11.4.2. Merck & Co., Inc.
11.4.2.1. Company Overview
11.4.2.2. Financial Performance
11.4.2.3. Product Benchmarking
11.4.2.4. Strategic Initiatives
11.4.3. Elanco
11.4.3.1. Company Overview
11.4.3.2. Financial Performance
11.4.3.3. Product Benchmarking
11.4.3.4. Strategic Initiatives
11.4.4. Boehringer Ingelheim International GmbH
11.4.4.1. Company Overview
11.4.4.2. Financial Performance
11.4.4.3. Product Benchmarking
11.4.4.4. Strategic Initiatives
11.4.5. Virbac
11.4.5.1. Company Overview
11.4.5.2. Financial Performance
11.4.5.3. Product Benchmarking
11.4.5.4. Strategic Initiatives
11.4.6. Vetoquinol
11.4.6.1. Company Overview
11.4.6.2. Financial Performance
11.4.6.3. Product Benchmarking
11.4.6.4. Strategic Initiatives
11.4.7. Dechra
11.4.7.1. Company Overview
11.4.7.2. Financial Performance
11.4.7.3. Product Benchmarking
11.4.7.4. Strategic Initiatives
11.4.8. Biofelix Pharma Group
11.4.8.1. Company Overview
11.4.8.2. Financial Performance
11.4.8.3. Product Benchmarking
11.4.8.4. Strategic Initiatives
11.4.9. TORAY INDUSTRIES, INC.
11.4.9.1. Company Overview
11.4.9.2. Financial Performance
11.4.9.3. Product Benchmarking
11.4.9.4. Strategic Initiatives
11.4.10. Bioiberica S.A.U.
11.4.10.1. Company Overview
11.4.10.2. Financial Performance
11.4.10.3. Product Benchmarking
11.4.10.4. Strategic Initiatives
11.4.11. Ceva
11.4.11.1. Company Overview
11.4.11.2. Financial Performance
11.4.11.3. Product Benchmarking
11.4.11.4. Strategic Initiatives
11.4.12. Bimeda, Inc.
11.4.12.1. Company Overview
11.4.12.2. Financial Performance
11.4.12.3. Product Benchmarking
11.4.12.4. Strategic Initiatives

$5,950
$6,950
$8,950

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings